Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus.

ABSTRACT:

Importance

Systemic lupus erythematosus (SLE) predisposes individuals to early cardiovascular (CV) events. While hydroxychloroquine is thought to mitigate CV risk factors, its protective role against CV events, particularly arterial ones, remains to be confirmed.

Objective

To evaluate the association between hydroxychloroquine and the risk of myocardial infarction (MI), stroke, and other thromboembolic events (OTEs) in patients with SLE.

Design, setting, and participants

This cohort study using a nested case-control design was conducted within the National French Healthcare Database (SNDS), which represents 99% of the French population, from 2010 to 2020. Participants were the cohort of all patients with SLE recorded in the SNDS. Patients with SLE experiencing CV even

SUBMITTER: Grimaldi L 

PROVIDER: S-EPMC11364994 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature